• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles Benzothiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles

Professional Introduction to 2-benzyl-2,3-dihydro-1lambda6,2-benzothiazole-1,1,3-trione (CAS No. 3416-59-9)

2-benzyl-2,3-dihydro-1lambda6,2-benzothiazole-1,1,3-trione, identified by the Chemical Abstracts Service Number (CAS No.) 3416-59-9, is a heterocyclic compound with significant structural and pharmacological interest. This trione derivative belongs to the benzothiazole class, a scaffold widely recognized for its biological activity in medicinal chemistry. The compound’s unique structural features—comprising a benzyl substituent, a dihydro intermediate, and a trione moiety—position it as a promising candidate for further exploration in drug discovery and synthetic chemistry.

The benzothiazole core is a privileged structure in pharmaceutical research due to its versatility in interacting with biological targets. Specifically, the 1lambda6 configuration suggests a strained system that may enhance binding affinity or modulate reactivity. The presence of the trione group introduces additional potential for hydrogen bonding and electrophilic interactions, which are critical for designing molecules with therapeutic efficacy. Such structural motifs have been leveraged in the development of antimicrobial, anti-inflammatory, and anticancer agents.

Recent advancements in computational chemistry have enabled more precise modeling of how 2-benzyl-2,3-dihydro-1lambda6,2-benzothiazole-1,1,3-trione (CAS No. 3416-59-9) might interact with biological macromolecules. Studies using molecular dynamics simulations and quantum mechanical calculations suggest that the compound’s trione group could serve as a key pharmacophore in binding to enzymes or receptors involved in metabolic pathways. This insight aligns with emerging research trends that emphasize structure-based drug design to optimize potency and selectivity.

In vitro investigations have begun to uncover the mechanistic potential of this compound. Preliminary assays indicate that derivatives of benzothiazole triones exhibit inhibitory effects on certain kinases and oxidoreductases, which are implicated in diseases such as cancer and neurodegeneration. The benzyl substituent appears to modulate the compound’s solubility and metabolic stability, making it an attractive candidate for further optimization. These findings are particularly relevant given the growing demand for small-molecule modulators that can selectively target aberrant signaling pathways.

The synthesis of 2-benzyl-2,3-dihydro-1lambda6,2-benzothiazole-1,1,3-trione (CAS No. 3416-59-9) presents an interesting challenge due to the need to construct the benzothiazole ring while maintaining regioselectivity during trione formation. Modern synthetic methodologies, including transition-metal-catalyzed cross-coupling reactions and organometallic chemistry techniques, have facilitated more efficient routes to this scaffold. Such improvements are crucial for enabling high-throughput screening campaigns aimed at identifying novel bioactive compounds.

Future research directions may focus on exploring analogs of this compound that exhibit enhanced pharmacokinetic properties or reduced off-target effects. For instance, modifications to the benzyl group could alter metabolic clearance rates or binding affinities for unintended targets. Additionally, exploring different heterocyclic linkages or substituents might reveal new biological activities not apparent in the parent structure. These explorations would benefit from interdisciplinary collaboration between synthetic chemists and biochemists to accelerate discovery.

The broader significance of compounds like 2-benzyl-2,3-dihydro-1lambda6,2-benzothiazole-1,1,3-trione (CAS No. 3416-59-9) lies in their potential contribution to addressing unmet medical needs through innovative chemical design. As drug resistance emerges as a global health concern, there is increasing emphasis on developing novel therapeutic agents with unique mechanisms of action. The benzothiazole trione scaffold offers a compelling starting point for such endeavors due to its structural versatility and demonstrated biological relevance.

In conclusion,2-benzyl-2,3-dihydro-1lambda6,2-benzothiazole-1,1,3-trione (CAS No. 3416-59-9) represents a structurally intriguing molecule with potential applications across multiple therapeutic areas. Ongoing research efforts aim to elucidate its full pharmacological profile while refining synthetic strategies for its production at scale. By leveraging advances in computational modeling and synthetic methodology,benzyl, trione, and other key structural elements will continue to inform the development of next-generation pharmaceuticals.

• 15448-99-4(2-Methyl-1,1-dioxo-1,2-benzothiazol-3-one)
• 7499-96-9(2-butyl-1,2-benzothiazol-3(2H)-one 1,1-dioxide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)